Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Metastases
Interventions
DRUG

Leuprorelin Acetate

Leuprorelin Acetate 45 mg, one injection every 6 months for 24 months

Trial Locations (35)

13009

Institut Paoli Calmettes, Marseille

13015

Hopital Nord, Marseille

21079

Chu Bocage, Dijon

22000

Centre Hopsitalier Prive - Polyclinique Du Littoral, Saint-Brieuc

25030

Chu Besancon, Besançon

29069

Chru de Brest, Brest

30029

Chu Caremeau, Nîmes

31059

Chu Rangueil, Toulouse

33000

Chu Bordeaux- Hopital Pellegrin, Bordeaux

33076

Institut Bergonie, Bordeaux

34070

Clinique Beausoleil, Montpellier

34295

Hopital Lapeyronie, Montpellier

35033

Chu Pontchaillou, Rennes

42013

Clinique Mutualiste, Saint-Etienne

44093

Chu Nantes, Nantes

51056

Institut Jean Godinot, Reims

54500

Chu de Nancy, Nancy

59037

Chru Lille, Lille

67090

Chu Strasbourg, Strasbourg

68024

Hopitaux Civils de Colmar, Strasbourg

69437

Hopital Edouard Herriot, Lyon

75010

Hopital Saint Louis, Paris

75014

Hopital Cochin, Paris

Institut Mutualiste Montsouris, Paris

75015

HEGP, Paris

75020

Hopital Tenon, Paris

75651

Hopital Pitie Salpetriere, Paris

76031

Hopital Charles Nicolle, Rouen

80000

Clinique Victor Pauchet, Amiens

85925

Centre Hospitalier Departemental, La Roche-sur-Yon

86000

Chu La Miletrie, Poitiers

87042

Chu Limoges, Limoges

92150

Hopital Foch, Suresnes

94010

Hopital Henri Mondor, Créteil

06002

Chu Pasteur, Nice

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

lead

UNICANCER

OTHER